---
title: 'Determinants of 5-year survival in patients with advanced NSCLC with PD-L1â‰¥50%
  treated with first-line pembrolizumab outside of clinical trials: results from the
  Pembro-real 5Y global registry'
date: '2025-02-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39904562/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250205170928&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: This study provides valuable real-world evidence that confirms
  the long-term efficacy of pembrolizumab outside of clinical trials. Hierarchical
  organization indicates ECOG-PS, age and PD-L1-TPS as the most important predictors
  of 5-year survival, potentially informing clinical ...'
disable_comments: true
---
CONCLUSION: This study provides valuable real-world evidence that confirms the long-term efficacy of pembrolizumab outside of clinical trials. Hierarchical organization indicates ECOG-PS, age and PD-L1-TPS as the most important predictors of 5-year survival, potentially informing clinical ...